Pfizer to discontinue twice-daily weight loss pill due to high rates of adverse side effects
Pfizer said it still plans to release phase two trial data on a once-a-day version of its weight loss drug, known as danuglipron, in mid-2024.
Similar Posts
Japan stocks higher at close of trade; Nikkei 225 up 0.43%
Post Content Post Views: 116
The vice-president of Germany’s central bank has a warning for lenders as insolvencies rise
Germany’s banks must increase provisions for loan losses, as corporate insolvencies and credit risks mount, according to Bundesbank Vice-President Claudia Buch. Post Views: 130
Panbela Therapeutics files to sell 4.26M shares of common stock for holders
Post Content Post Views: 115
Bank of England economist supports firm stance on inflation
Post Content Post Views: 111
Taiwan 2024 elections: These are the three parties vying to replace President Tsai Ing-Wen
The outcome of this election will likely influence testy U.S.-China ties and impact security in the broader Asia-Pacific region. Post Views: 117
China’s property sector needs more government support as crisis deepens
China’s property market, which makes up a substantial chunk of the country’s economy, needs more government support to prevent further deterioration, analysts said. Post Views: 141